NASDAQ · LIMN
Healthcare · Biotechnology
$3.51
Down-$0.01 (-0.28%)
Updated Sep 16, 2026, 12:50 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
LIMN closed at $3.51 after 20 trading sessions, down 46.00% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $3.50 | $3.58 | $3.4147 | $3.51 | 14.26K |
| Sep 14, 2026 | $3.45 | $3.615 | $3.29 | $3.52 | 38.01K |
| Sep 11, 2026 | $3.63 | $3.675 | $3.46 | $3.47 | 31.46K |
| Sep 10, 2026 | $3.54 | $3.80 | $3.4505 | $3.63 | 20.18K |
| Sep 9, 2026 | $3.60 | $3.65 | $3.48 | $3.48 | 20.84K |
| Sep 8, 2026 | $3.72 | $3.725 | $3.52 | $3.62 | 26.3K |
| Sep 4, 2026 | $3.70 | $3.82 | $3.65 | $3.71 | 23.26K |
| Sep 3, 2026 | $3.64 | $3.91 | $3.6101 | $3.70 | 22.53K |
| Sep 2, 2026 | $3.86 | $4.00 | $3.70 | $3.84 | 31.8K |
| Sep 1, 2026 | $3.80 | $3.80 | $3.42 | $3.645 | 53.45K |
| Aug 31, 2026 | $4.24 | $4.26 | $3.80 | $3.86 | 51.65K |
| Aug 28, 2026 | $4.36 | $4.74 | $4.23 | $4.23 | 40.52K |
| Aug 27, 2026 | $4.37 | $4.88 | $4.37 | $4.40 | 52.08K |
| Aug 26, 2026 | $4.42 | $4.545 | $4.26 | $4.41 | 49.39K |
| Aug 25, 2026 | $4.64 | $4.8399 | $4.35 | $4.61 | 73.21K |
| Aug 24, 2026 | $5.03 | $5.04 | $4.6101 | $4.67 | 83.12K |
| Aug 21, 2026 | $5.53 | $5.8756 | $5.15 | $5.16 | 117.36K |
| Aug 20, 2026 | $5.69 | $5.945 | $5.395 | $5.63 | 71.55K |
| Aug 19, 2026 | $5.535 | $5.90 | $5.25 | $5.585 | 94.09K |
| Aug 18, 2026 | $6.50 | $7.035 | $6.50 | $6.50 | 77.06K |
The latest Smart Investors Daily articles mentioning LIMN.
LIMN research
Company profile and research snapshot.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Aug 24, 2026
Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announced that it has engaged Synex Consulting Ltd.
Benzinga · Aug 18, 2026
Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company") today announced that its board of directors has adopted resolutions approving a reverse stock split of its common stock, par value
Yahoo · Aug 13, 2026
FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, today announced that its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026, and that the Nasdaq Hearings Panel (the “Panel”) has granted the Company additional time to demonstrate compliance with Nasdaq’s minimum bid pr
Benzinga · Jul 17, 2026
Gainers Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's regular session. The company's market cap stands at $21.6 million. Kalaris Therapeutics (NASDAQ:KLRS) shares
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LIMN.
